This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third Perspective: Analyzing Reata Pharma’s MOXIe study of omaveloxolone for the treatment of Friedreich's ataxia
Ticker(s): RETA, LRMR, DSGNWho's the expert?
Institution: Murdoch Children's Research Institute
- Medical Director of Victorian Clinical Genetics Services and Director of the Bruce Lefroy Centre at the Murdoch Children’s Research Institute.
- Oversees a clinic that sees ~100 people Friedreich ataxia annually.
- Clinical and research interests in genetic screening and neurogenetics and has studied Friedreich ataxia for more than 20 years. His team identified resveratrol as a potential treatment and is now conducting a randomised placebo-controlled trial of this agent.
Interview GoalTo understand the needs of Friedreich's ataxia patients, and evaluate omaveloxolone’s potential.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
